RYAM

Analyst Note: RYAM (Rayonier Advanced Materials Inc.)

Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

• Conservative Entry: 8.54
• Current Price: 9.05
• Extension: +6.0% vs conservative entry.
• Breakout Level: 8.54 (Conservative).
• ATR Context: ATR at breakout was 4.2% (High). Current ATR is 4.7% (High). This indicates elevated volatility but within the historical "sweet spot" (4–6%) for structural quality, suggesting the move is supported by genuine volume/interest rather than thin liquidity.

2. Thesis Layer

• Thesis Classification: TACTICAL / Setup-Led.
• Macro Context: There is no named secular thesis attached to this specific setup as of 2026-06-20. The conviction must be derived entirely from the quality of the technical structure (the Coil) and the immediate business fundamentals disclosed in the Q1 2026 earnings cycle. We are not trading a macro narrative here; we are trading a structural inflection point supported by operational improvements.

3. Business Fundamentals (As of 2026-06-20)

Rayonier Advanced Materials Inc. operates as a global leader in high-purity cellulose and derivatives. The business model relies on specialized assets to produce cellulose specialties (filters, food, pharma, plastics) and commodities (fluff pulp, viscose pulp).

Key Operational Updates (Source: Q1 2026 Earnings & Filings):

• Commercialization & Pricing: The company reported Adjusted EBITDA of $8 million for the quarter. Management highlighted a 17% year-over-year increase in average Cellulose Specialty (CS) sales prices.
• Volume Guidance: Management is targeting approximately 10,000 metric tons of annual sales in 2026 for specific new markets, with a path to 20,000 metric tons for softwood high-yield pulp rolls.
• Pricing Power: The company has secured the majority of its 2026 CS volume at pricing "meaningfully higher than 2025."
• Asset Rationalization:
• Operations at the Temiscaming cellulose plant were indefinitely suspended in July 2024 to mitigate capital needs.
• In Q1 2026, management determined to permanently cease DWP (Dissolving Wood Pulp) production at Temiscaming.
• The company now operates three facilities with a combined capacity of 885,000 MTs, excluding the 140,000 MTs at Temiscaming.
• Cash Flow & Capex: Management expects full-year EBITDA to be higher than 2025 and to generate positive free cash flow. Capital expenditures are being prioritized for reduction to focus on near-term cash generation and deleveraging.
• New Product Expansion: In October 2025, the Kallima® portfolio was expanded with an enhanced freezer application for folding carton board.

4. Archetype and Conviction

• Archetype: Structurally Broken (Recovery / Turnaround).
• *Rationale:* The company has undergone a significant structural reset. The suspension of the Temiscaming plant and the permanent cessation of DWP production represent a "broken" state that has been managed to stop the bleeding. The current setup reflects a recovery phase where the company is pivoting from a distressed commodity producer to a higher-margin specialty player.
• Conviction Stack:
• Thesis Strength: Moderate. It is a tactical play on operational turnaround, not a secular growth story.
• Evidence Quality: High. The Q1 2026 data provides concrete metrics on EBITDA ($8M), pricing (+17%), and volume targets.
• Structural Quality: High. The ATR at breakout (4.2%) and current ATR (4.7%) fall into the "High" bucket (4–6%), which is the historical sweet spot for valid breakouts. The setup is not "weak" (sub-threshold) nor "extreme" (>8%).
• Rerating Potential: Moderate to High. The shift from "commodity" to "specialty" (CS volumes up 15-20%, new Kallima applications) suggests a multiple expansion if the EBITDA targets are met.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners:
• Confirmation of the 10,000–20,000 MT volume targets in the next quarterly report.
• Sustained EBITDA growth above the $8M quarterly run-rate.
• Successful commercialization of the new Kallima® freezer application.
• Gaps in Evidence:
• Debt Levels: While management mentions "deleveraging," specific debt-to-EBITDA ratios or interest coverage ratios for 2026 are not explicitly detailed in the provided evidence snippets.
• Customer Concentration: The "large international petrochemicals company" for the bioethanol offtake is not named, leaving a gap on counterparty risk assessment.
• 2026 Full Year EBITDA: Management expects "higher than 2025," but the specific 2025 baseline or the 2026 target number is not quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Adjusted EBITDA of $8 million in Q1 2026; 17% year-over-year increase in average CS sales price; confirmed path to positive free cash flow for full year 2026; structural reset of Temiscaming plant completed with focus on higher-margin specialties. Key risks: Failure to meet 2026 volume targets (10k-20k MT); continued volatility in commodity fluff/viscose pricing; potential delay in new product commercialization; lack of specific debt reduction metrics in public filings. Sizing hint: Standard position size for a confirmed breakout with high ATR; reduce size if volatility spikes above 6% ATR. Expected path: Management executes on volume growth in high-value markets while maintaining pricing discipline; EBITDA expands sequentially as new product lines ramp; deleveraging improves balance sheet flexibility for capital returns. Expected horizon: 6 to 12 months for the 2026 volume targets to materialize and for the market to fully price the turnaround. Failure mode to watch: A sustained drop in CS pricing or a miss on the 2026 volume guidance that forces a revision of the EBITDA outlook.